Skip to Main Content

Paper Details

Pharmacogenomic profiling reveals molecular features of chemotherapy resistance in IDH wild-type primary glioblastoma.
Genome Med
5
2023
-wt GBMs, 5-aminolevulinic acid, ANXA3, CDKN2A/B, EGFR, EGR4, GBM, GBMs, GSC, GSCs, IDH, IDH wild, IDH-, IDH-wt, IDH-wt GBM, LRRC3, PAPPA, PTEN, TMZ, glioma, glioma stem-like cells, isocitrate, isocitrate dehydrogenase wild, mesenchymal, mesenchymal/proneural expression subtypes, multisector GSCs, patient, patients, primary glioblastoma, proneural expression, sensitive samples, temozolomide, tumor, wt GBMs
Author NameAffiliation
Harim KooInstitute for Refractory Cancer Research, Research Institute for Future Medicine, Samsung Medical Center
Harim KooKorea University College of Medicine
Harim KooNational Cancer Center
Harim KooResearch Institute and Hospital, National Cancer Center
Sang ShinInstitute for Refractory Cancer Research, Research Institute for Future Medicine, Samsung Medical Center
Donggeon KimInstitute for Refractory Cancer Research, Research Institute for Future Medicine, Samsung Medical Center
Seung Won ChoiColumbia University
Jason K SaKorea University College of Medicine
Yun Jee SeoInstitute for Refractory Cancer Research, Research Institute for Future Medicine, Samsung Medical Center
Jeong-Woo OhInstitute for Refractory Cancer Research, Research Institute for Future Medicine, Samsung Medical Center
Yong-Jun KwonInstitute for Refractory Cancer Research, Research Institute for Future Medicine, Samsung Medical Center
Woong-Yang ParkSamsung Advanced Institute for Health Sciences and Technology, Sungkyunkwan University
Woong-Yang ParkSamsung Genome Institute, Samsung Medical Center
Woong-Yang ParkSamsung Advanced Institute for Health Sciences and Technology, Sungkyunkwan University
Woong-Yang ParkSamsung Genome Institute, Samsung Medical Center
Doo-Sik KongSamsung Medical Center and Sungkyunkwan University School of Medicine
Doo-Sik KongSamsung Medical Center and Sungkyunkwan University School of Medicine
Ho Jun SeolSamsung Medical Center and Sungkyunkwan University School of Medicine
Ho Jun SeolSamsung Medical Center and Sungkyunkwan University School of Medicine
Jung-Il LeeSamsung Medical Center and Sungkyunkwan University School of Medicine
Jung-Il LeeSamsung Medical Center and Sungkyunkwan University School of Medicine
Chul-Kee ParkCollege of Medicine, Seoul National University and Seoul National University Hospital
Hye Won LeeCenter for Urologic Cancer, National Cancer Center
Hye Won LeeSamsung Medical Center
Yeup YoonInstitute for Refractory Cancer Research, Research Institute for Future Medicine, Samsung Medical Center
Yeup YoonSamsung Advanced Institute for Health Sciences and Technology, Sungkyunkwan University
Yeup YoonSungkyunkwan University
Jiguang WangThe Hong Kong University of Science and Technology
Jiguang WangThe Hong Kong University of Science and Technology
Jiguang WangHong Kong Center for Neurodegenerative Diseases
Jiguang WangHKUST Shenzhen-Hong Kong Collaborative Innovation Research Institute
  • 1 - 31

Datasets

Release 1.2